Business Description
Humacyte Inc
NAICS : 325412
SIC : 2834
ISIN : US44486Q1031
Description
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.04 | |||||
| Equity-to-Asset | 0.36 | |||||
| Debt-to-Equity | 0.92 | |||||
| Debt-to-EBITDA | -0.76 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 10.85 | |||||
| 9-Day RSI | 24.09 | |||||
| 14-Day RSI | 33.63 | |||||
| 6-1 Month Momentum % | 20.86 | |||||
| 12-1 Month Momentum % | 1.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.59 | |||||
| Quick Ratio | 10.59 | |||||
| Cash Ratio | 10.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -1.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -85.12 | |||||
| ROA % | -43.13 | |||||
| ROIC % | -146.48 | |||||
| ROC (Joel Greenblatt) % | -162.87 | |||||
| ROCE % | -43.41 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.87 | |||||
| Price-to-Tangible-Book | 4.88 | |||||
| EV-to-EBIT | -2.92 | |||||
| EV-to-EBITDA | -3.25 | |||||
| EV-to-Forward-Revenue | 74.88 | |||||
| EV-to-FCF | -3.01 | |||||
| Price-to-Net-Current-Asset-Value | 22.15 | |||||
| Price-to-Net-Cash | 41.14 | |||||
| Earnings Yield (Greenblatt) % | -34.25 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HUMA
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Humacyte Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.87 | ||
| Beta | 0 | ||
| Volatility % | 56.77 | ||
| 14-Day RSI | 33.63 | ||
| 14-Day ATR ($) | 0.295209 | ||
| 20-Day SMA ($) | 3.606 | ||
| 12-1 Month Momentum % | 1.96 | ||
| 52-Week Range ($) | 1.96 - 5.6 | ||
| Shares Outstanding (Mil) | 103.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Humacyte Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Humacyte Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Humacyte Inc Frequently Asked Questions
What is Humacyte Inc(HUMA)'s stock price today?
The current price of HUMA is $2.88. The 52 week high of HUMA is $5.60 and 52 week low is $1.96.
When is next earnings date of Humacyte Inc(HUMA)?
The next earnings date of Humacyte Inc(HUMA) is 2023-11-10 Est..
Does Humacyte Inc(HUMA) pay dividends? If so, how much?
Humacyte Inc(HUMA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers